PARP抑制剂治疗铂耐药卵巢癌的研究进展

国际肿瘤学杂志››2021,Vol. 48››Issue (3): 180-183.doi:10.3760/cma.j.cn371439-20200629-00036

PARP抑制剂治疗铂耐药卵巢癌的研究进展

李晨曦¹, 赵宏伟^2,^*()

¹山西医科大学第二临床医学院,太原 030001
²山西省肿瘤医院妇二科,太原 030001

收稿日期:2020-06-29修回日期:2020-07-26出版日期:2021-03-08发布日期:2021-03-25
通讯作者:赵宏伟 E-mail:inmind20060829@126.com
基金资助:
CSCO-恒瑞肿瘤研究基金(Y-HR2018-330);山西省重点研发计划(201903D321174)

Advances in the treatment of platinum-resistant ovarian cancer with PARP inhibitors

Li Chenxi¹, Zhao Hongwei^2,^*()

¹Second Clinical College, Shanxi Medical University, Taiyuan 030001, China
²Second Department of Gynecology, Shanxi Provincial Cancer Hospital, Taiyuan 030001, China

Received:2020-06-29Revised:2020-07-26Online:2021-03-08Published:2021-03-25
Contact:Zhao Hongwei E-mail:inmind20060829@126.com
Supported by:
CSCO-Hengrui Cancer Research Fund(Y-HR2018-330);Key Research and Development Program of Shanxi Province of China(201903D321174)

摘要/Abstract

摘要：

聚ADP核糖聚合酶(PARP)抑制剂是一种治疗卵巢癌的靶向生物制剂,其适用人群主要是对铂治疗敏感的卵巢癌患者。但有临床试验数据表明PARP抑制剂对铂耐药或铂难治卵巢癌患者也有一定治疗效果,未来可能成为卵巢癌患者治疗的新希望。

李晨曦, 赵宏伟. PARP抑制剂治疗铂耐药卵巢癌的研究进展[J]. 国际肿瘤学杂志, 2021, 48(3): 180-183.

Li Chenxi, Zhao Hongwei. Advances in the treatment of platinum-resistant ovarian cancer with PARP inhibitors[J]. Journal of International Oncology, 2021, 48(3): 180-183.

参考文献29

[1]	Gaona-Luviano P, Medina-Gaona LA, Magaña-Pérez K. Epidemiology of ovarian cancer [J]. Chin Clin Oncol, 2020,9(4):47. DOI: 10.21037/cco-20-34. doi:10.21037/cco
[2]	Pujade-Lauraine E, Combe P. Recurrent ovarian cancer[J]. Ann Oncol, 2016,27 Suppl 1: i63-i65. DOI: 10.1093/annonc/mdw079.
[3]	Scott CL, Swisher EM, Kaufmann SH. Poly (ADP-ribose) polyme-rase inhibitors: recent advances and future development[J]. J Clin Oncol, 2015,33(12):1397-1406. DOI: 10.1200/JCO.2014.58.8848. doi:10.1200/JCO.2014.58.8848pmid:25779564
[4]	李宁, 吴令英. PARP抑制剂在上皮性卵巢癌的应用现状[J]. 实用妇产科杂志, 2020,36(2):88-92.
[5]	Scott LJ. Niraparib: first global approval[J]. Drugs, 2017,77(9):1029-1034. DOI: 10.1007/s40265-017-0752-y.
[6]	Syed YY. Rucaparib: first global approval[J]. Drugs, 2017,77(5):585-592. DOI: 10.1007/s40265-017-0716-2. doi:10.1007/s40265-017-0716-2pmid:28247266
[7]	Deeks ED. Olaparib: first global approval[J]. Drugs, 2015,75(2):231-240. DOI: 10.1007/s40265-015-0345-6. pmid:25616434
[8]	Pujade-Lauraine E, Banerjee S, Pignata S. Management of platinum-resistant, relapsed epithelial ovarian cancer and new drug perspectives[J]. J Clin Oncol, 2019,37(27):2437-2448. DOI: 10.1200/JCO.19.00194. pmid:31403868
[9]	Washington CR, Richardson DL, Moore KN. Olaparib in the treatment of ovarian cancer[J]. Future Oncol, 2019,15(30):3435-3449. DOI: 10.2217/fon-2019-0271. doi:10.2217/fon-2019-0271pmid:31478762
[10]	Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation[J]. J Clin Oncol, 2015,33(3):244-250. DOI: 10.1200/JCO.2014.56.2728. pmid:25366685
[11]	Kim H, George E, Ragland R, et al. Targeting the ATR/CHK1 axis with PARP inhibition results in tumor regression in BRCA-mutant ovarian cancer models[J]. Clin Cancer Res, 2017,23(12):3097-3108. DOI: 10.1158/1078-0432.CCR-16-2273.
[12]	Domchek SM, Aghajanian C, Shapira-Frommer R, et al. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy[J]. Gynecol Oncol, 2016,140(2):199-203. DOI: 10.1016/j.ygyno.2015.12.020.
[13]	Jenner ZB, Sood AK, Coleman RL. Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy[J]. Future Oncol, 2016,12(12):1439-1456. DOI: 10.2217/fon-2016-0002. pmid:27087632
[14]	Sabatucci I, Maltese G, Lepori S, et al. Rucaparib: a new treatment option for ovarian cancer[J]. Expert Opin Pharmacother, 2018,19(7):765-771. DOI: 10.1080/14656566.2018.1464557. doi:10.1080/14656566.2018.1464557pmid:29672168
[15]	Dal Molin GZ, Westin SN, Coleman RL. Rucaparib in ovarian can-cer: extending the use of PARP inhibitors in the recurrent disease[J]. Future Oncol, 2018,14(30):3101-3110. DOI: 10.2217/fon-2018-0215. doi:10.2217/fon-2018-0215pmid:30105925
[16]	Oza AM, Tinker AV, Oaknin A, et al. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL2[J]. Gynecol Oncol, 2017,147(2):267-275. DOI: 10.1016/j.ygyno.2017.08.022. pmid:28882436
[17]	Moore KN, Secord AA, Geller MA, et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial[J]. Lancet Oncol, 2019,20(5):636-648. DOI: 10.1016/S1470-2045(19)30029-4. doi:10.1016/S1470-2045(19)30029-4pmid:30948273
[18]	Moore KN, Secord AA, Geller MA, et al. QUADRA: a phase Ⅱ, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: results from the tBRCAmut subset[J]. Ann Oncol, 2018,29(suppl 8):944P.DOI: 10.1093/annonc/mdy285.152.
[19]	Perez-Fidalgo JA, Iglesias M, Bohn U, et al. GEICO1601-ROLANDO: a multicentric single arm phase Ⅱ clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer[J]. Future Sci OA, 2019,5(2):FSO370. DOI: 10.4155/fsoa-2018-0107. pmid:30820349
[20]	Konstantinopoulos PA, Barry WT, Birrer M, et al. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial[J]. Lancet Oncol, 2019,20(4):570-580. DOI: 10.1016/S1470-2045(18)30905-7. doi:10.1016/S1470-2045(18)30905-7pmid:30880072
[21]	薛晨, 赵月, 石光, 等. PD-1/PD-L1抑制剂在卵巢癌中的研究进展[J]. 国际肿瘤学杂志, 2020,47(5):312-315. DOI: 10.3760/cma.j.cn371439-20200321-00026.
[22]	Shen J, Zhao W, Ju Z, et al. PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness[J]. Cancer Res, 2019,79(2):311-319. DOI: 10.1158/0008-5472.CAN-18-1003. doi:10.1158/0008-5472.CAN-18-1003pmid:30482774
[23]	Konstantinopoulos PA, Waggoner S, Vidal GA, et al. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma[J]. JAMA Oncol, 2019,5(8):1141-1149. DOI: 10.1001/jamaoncol.2019.1048. doi:10.1001/jamaoncol.2019.1048
[24]	Varga A, Piha-Paul S, Ott PA, et al. Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: analysis of KEYNOTE-028[J]. Gynecol Oncol, 2019,152(2):243-250. DOI: 10.1016/j.ygyno.2018.11.017. doi:10.1016/j.ygyno.2018.11.017
[25]	Matulonis UA, Shapira-Frommer R, Santin AD, et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase Ⅱ KEYNOTE-100 study[J]. Ann Oncol, 2019,30(7):1080-1087. DOI: 10.1093/annonc/mdz135. doi:10.1093/annonc/mdz135pmid:31046082
[26]	Ivy SP, Liu JF, Lee JM, et al. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer[J]. Expert Opin Investig Drugs, 2016,25(5):597-611. DOI: 10.1517/13543784.2016.1156857. doi:10.1517/13543784.2016.1156857pmid:26899229
[27]	Liu JF, Tolaney SM, Birrer M, et al. A phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer[J]. Eur J Cancer, 2013,49(14):2972-2978. DOI: 10.1016/j.ejca.2013.05.020. doi:10.1016/j.ejca.2013.05.020pmid:23810467
[28]	Liu JF, Barry WT, Birrer M, et al. Overall survival and updated progression-free survival outcomes in a randomized phase Ⅱ study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer[J]. Ann Oncol, 2019,30(4):551-557. DOI: 10.1093/annonc/mdz018. doi:10.1093/annonc/mdz018pmid:30753272
[29]	Boussios S, Karihtala P, Moschetta M, et al. Combined strategies with poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer: a literature review[J]. Diagnostics (Basel), 2019,9(3):87. DOI: 10.3390/diagnostics9030087.

PARP抑制剂治疗铂耐药卵巢癌的研究进展

Advances in the treatment of platinum-resistant ovarian cancer with PARP inhibitors

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献29

相关文章15

编辑推荐

Metrics

本文评价

[1]	钱晓涛, 石子宜, 胡格, 吴晓维.Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	姚益新, 沈煜霖.血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[4]	龚艳, 陈洪雷.微RNA调控卵巢癌顺铂耐药的机制研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 186-190.
[5]	姜溪, 武永存, 梁艳, 楚丽, 段颖欣, 王力军, 霍俊杰.派安普利单抗联合化疗对晚期非小细胞肺癌患者血管生成及循环内皮细胞的影响[J]. 国际肿瘤学杂志, 2024, 51(2): 89-94.
[6]	安荣, 刘美华, 王佩晨, 王晓慧.Nrf2在卵巢癌中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(8): 493-497.
[7]	李晨曦, 赵宏伟.二次肿瘤细胞减灭术治疗初始减瘤手术不满意铂敏感复发性卵巢癌的预后及影响因素分析[J]. 国际肿瘤学杂志, 2023, 50(6): 342-347.
[8]	杨丽蓉, 王羽丰.预测浆液性卵巢癌术后复发远处转移风险机器学习模型的构建[J]. 国际肿瘤学杂志, 2023, 50(4): 220-226.
[9]	范珊琳, 汪品秀, 孔飞, 周玉洁, 袁文臻.胃癌新辅助化疗后肿瘤退缩分级预测因素的研究进展[J]. 国际肿瘤学杂志, 2023, 50(2): 112-116.
[10]	巩合义, 伊艳, 张健, 李宝生.局部晚期可手术食管癌经新辅助放化疗达临床完全缓解后的处理策略[J]. 国际肿瘤学杂志, 2023, 50(12): 745-750.
[11]	孙琦, 李文倩, 解友邦, 周厚法.化疗后骨髓抑制机制的研究进展[J]. 国际肿瘤学杂志, 2023, 50(1): 33-36.
[12]	吴浦嫄, 祁亮, 王涛, 史敏科, 孙雨薇, 王立峰, 刘宝瑞, 闫婧, 任伟.基于高频复发区改良临床靶区的术后放疗在食管鳞状细胞癌中的疗效研究[J]. 国际肿瘤学杂志, 2022, 49(8): 464-472.
[13]	刘松, 于广计, 王庆东.DEBIRI-TACE联合瑞戈非尼三线以上治疗结直肠癌肝转移的疗效及影响因素分析[J]. 国际肿瘤学杂志, 2022, 49(7): 400-407.
[14]	张慎锋, 刘杰, 祝情情, 阚士峰, 孙晋军, 王涛, 邱梅清.长春瑞滨节拍化疗治疗一线失败后驱动基因阴性晚期老年非小细胞肺癌的疗效和安全性[J]. 国际肿瘤学杂志, 2022, 49(7): 441-443.
[15]	杜佳, 李娟, 李钱, 陈姝, 单锦露.新辅助放化疗联合动脉栓塞灌注治疗局部晚期直肠癌1例[J]. 国际肿瘤学杂志, 2022, 49(6): 383-384.